Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
if it does i will buy... alot
sell me your shares put it out here how many dry powder sitting and waiting hopefully its enough shares to be worth it
groundhog day
Absolutely... Very Powerful...
The game is still being played. They do what they do and we do what we do. Ask your-self do you really think they came this far for pennies. LONG NWBO. Linda and the team are very very smart. lets see what happens
Hi learning how long have you been around nwbo. Ive been around 7 or so. I get it . I guess my question is why are you still on ihub posting? Do you still have a intrest in the stock going up or is it that you want to help others from investing in the company? I am not trying to out you in any way I was just trying to understand your purpose.
4 golden nuggets for $NWBO
1. OS instead of PFS
2. Contemporaneous controls
3. Data includes a second trial in rGBM!!!
4. Oct read out
Two chances to win(!?) and rGBM is a greater unmet need.
< Back to search results
Print Download
Summary
EudraCT Number: 2011-001977-13
Sponsor's Protocol Code Number: 020221
National Competent Authority: UK - MHRA
Clinical Trial Type: EEA CTA
Trial Status: Restarted
Date on which this record was first entered in the EudraCT database: 2012-07-09
Trial results
Index
A. PROTOCOL INFORMATION
B. SPONSOR INFORMATION
C. APPLICANT IDENTIFICATION
D. IMP IDENTIFICATION
D.8 INFORMATION ON PLACEBO
E. GENERAL INFORMATION ON THE TRIAL
F. POPULATION OF TRIAL SUBJECTS
G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
P. END OF TRIAL
Expand All Collapse All
A. Protocol Information
A.1 Member State Concerned UK - MHRA
A.2 EudraCT number 2011-001977-13
A.3 Full title of the trial
A Phase III clinical trial evaluating DCVax®-L, autologous dendritic cells (DC) pulsed with tumor lysate antigen for the treatment of glioblastoma multiforme (GBM)
A.3.1 Title of the trial for lay people, in easily understood, i.e. non-technical, language
A Clinical Trial Evaluating DCVax®-L, Self-Derived Dendritic Cells Mixed with Tumor Proteins for the Treatment of Glioblastoma, a Type of Brain cancer
A.3.2 Name or abbreviated title of the trial where available
DCVax®-L for GBM
A.4.1 Sponsor's protocol code number 020221
A.5.2 US NCT (ClinicalTrials.gov registry) number NCT00045968
A.7 Trial is part of a Paediatric Investigation Plan No
A.8 EMA Decision number of Paediatric Investigation Plan
B. Sponsor Information
B.Sponsor: 1
B.1.1 Name of Sponsor Northwest Biotherapeutics Inc
B.1.3.4 Country United States
B.3.1 and B.3.2 Status of the sponsor Commercial
B.4 Source(s) of Monetary or Material Support for the clinical trial:
B.4.1 Name of organisation providing support Northwest Biotherapeutics Inc
B.4.2 Country United States
B.5 Contact point designated by the sponsor for further information on the trial
B.5.1 Name of organisation Northwest Biotherapeutics BV
B.5.2 Functional name of contact point Marnix Bosch
B.5.3 Address:
B.5.3.1 Street Address Kingsforden 151
B.5.3.2 Town/ city Amsterdam
B.5.3.3 Post code 1043GR
B.5.3.4 Country Netherlands
B.5.4 Telephone number +31638667526
B.5.5 Fax number +31206120203
B.5.6 E-mail marnix@nwbio.com
D. IMP Identification
D.IMP: 1
D.1.2 and D.1.3 IMP Role Test
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation No
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community Yes
D.2.5.1 Orphan drug designation number EU/3/07/431
D.3 Description of the IMP
D.3.1 Product name DCVax®-L
D.3.4 Pharmaceutical form Suspension for injection
D.3.4.1 Specific paediatric formulation No
D.3.7 Routes of administration for this IMP Intradermal use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN Canpuldencel-T
D.3.9.2 Current sponsor code DCVax-L
D.3.9.3 Other descriptive name Tumor lysate loaded DC
D.3.10 Strength
D.3.10.1 Concentration unit Other
D.3.10.2 Concentration type equal
D.3.10.3 Concentration number 1250000
D.3.11 The IMP contains an:
D.3.11.1 Active substance of chemical origin No
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
The IMP is a:
D.3.11.3 Advanced Therapy IMP (ATIMP) Yes
D.3.11.3.1 Somatic cell therapy medicinal product Yes
D.3.11.3.2 Gene therapy medical product No
D.3.11.3.3 Tissue Engineered Product No
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device) No
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product No
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy No
D.3.11.5 Radiopharmaceutical medicinal product No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum) No
D.3.11.7 Plasma derived medicinal product No
D.3.11.8 Extractive medicinal product No
D.3.11.9 Recombinant medicinal product No
D.3.11.10 Medicinal product containing genetically modified organisms No
D.3.11.11 Herbal medicinal product No
D.3.11.12 Homeopathic medicinal product No
D.3.11.13 Another type of medicinal product No
D.8 Information on Placebo
D.8 Placebo: 1
D.8.1 Is a Placebo used in this Trial? Yes
D.8.3 Pharmaceutical form of the placebo Suspension for injection
D.8.4 Route of administration of the placebo Intradermal use
E. General Information on the Trial
E.1 Medical condition or disease under investigation
E.1.1 Medical condition(s) being investigated
Glioblastoma Multiforme
E.1.1.1 Medical condition in easily understood language
Brain cancer
E.1.1.2 Therapeutic area Diseases [C] - Cancer [C04]
MedDRA Classification
E.1.2 Medical condition or disease under investigation
E.1.2 Version 20.0
E.1.2 Level PT
E.1.2 Classification code 10018337
E.1.2 Term Glioblastoma multiforme
E.1.2 System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
E.1.3 Condition being studied is a rare disease Yes
E.2 Objective of the trial
E.2.1 Main objective of the trial
The primary objective of this study is to compare overall survival (OS) between patients randomized to DCVax-L and control patients from comparable, contemporaneous trials who received standard of care therapy only, in patients with newly diagnosed glioblastoma. This endpoint will be assessed using 3 different analyses
E.2.2 Secondary objectives of the trial
The first secondary objective is to compare overall survival (OS) between patients randomized to placebo who received DCVax-L treatment following disease recurrence and control patients from
comparable, contemporaneous clinical trials, in patients with recurrent GBM.
E.2.3 Trial contains a sub-study No
E.3 Principal inclusion criteria
Determined at pre-screening
• Patients ≥18 and ≤70 years of age at surgery
• Patients must be able to understand and sign the informed consent. The consent for tumor donation may be signed by a legally authorized representative (LAR) if allowed by the institution.
• Patients must have a life expectancy of ≥8 weeks determined at or around surgery, and prior to pre-leukapheresis
• Primary therapy must consist of surgical resection with the intent for a gross or near gross total resection of the contrast-enhancing tumor mass as confirmed by central review, followed by external beam radiation therapy and concurrent temozolomide chemotherapy.
• Patients with newly diagnosed, unilateral GBM (Grade IV) without metastases are eligible for this protocol.
• All Patients must have sufficient tumor lysate protein that was generated from the surgically obtained tumor material.
Determined at pre-leukapheresis
• Patients must have adequate bone marrow function (
• Adequate liver function
Determined at baseline (or baseline2 for pseudoprogression patients)
• Patients must have a KPS rating of ≥70 at the Baseline Visit (Visit 5)
• Patients may have received steroid therapy as part of their primary
treatment. Steroid treatment must preferably be stopped; or if continued steroid use is clinically indicated, be tapered down to 2-4 mg dexamethasone qd at least 7 days prior to the first immunization.
• Patients must be willing to forego cytotoxic anti-tumor therapies except temozolomide while being treated with study drug.
• A minimum of 5 immunizations must be available for treatment as determined by the contracted manufacturer.
E.4 Principal exclusion criteria
Determined at pre-screening
• History of prior malignancy except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer or other cancers that were deemed fully resolved 5 or more years prior to Visit 1 (surgery) of
the study.
• History of immunodeficiency disease or unresolved autoimmune disease
• Known HIV-1,2, HTLV-1,2 or Hepatitis B, C infection
• Pregnancy
• Inability to obtain informed consent because of psychiatric or complicating medical problems.
• Any known genetic cancer-susceptibility syndromes.
Determined at or around surgery
• Bilateral or metastatic disease detected at diagnosis, during surgery or at post-surgical magnetic resonance imaging (MRI). Tumors may cross into, but not beyond the corpus callosum.
• Post operative MRI scan evidence of biopsy only without significant tumor resection.
• Implantation of Gliadel® wafers (polifeprosan 20 with carmustine implant) at surgery.
• Positive test(s) for infectious agents (HIV 1 and 2, Anti-HIV-1,2, Hepatitis B, HBsAg, Anti HBc, Hepatitis C, Anti-HCV-Ab, Syphilis) that would preclude eligibility for tumor procurement and processing per manufacturing guidelines.
Determined at pre-leukapheresis
• Positive HIV-1, HIV-2, HTLV-1, 2, hepatitis B surface antigen, or hepatitis C antibody.
• Patients with organ allografts.
• Allergies to reagents used in this study.
• Patients who are unable to stop or taper steroid treatment to less than 8mg of dexamethasone qd prior to leukapheresis
• Inability or unwillingness to return for required visits and follow-up exams.
• Any previous cytotoxic drug therapies for the current disease. *note, cytotoxic therapy received for previous malignancies (resolved greater than 5 years prior) is not excluded
Determined at or prior to baseline
• Patients who have evidence of disease progression (including possible pseudoprogression) as determined by central review are not eligible for the study
• Patients taking medications that might affect immune function and that have documented anti-tumor activity.
• Acute infection: any active viral, bacterial, or fungal infection that requires specific therapy. Antibiotic therapy must be completed at least 7 days prior to the first immunization.
• Active uncontrolled infection e.g. a sexually transmitted disease (STD), herpes, uncontrolled tuberculosis, malaria, etc.
• Fever ≥101.5oF. If considered possibly transient, retesting is allowed.
• Unstable or severe intercurrent medical conditions e.g., unstable angina, uncontrolled arrhythmias, Crohn's Disease, ulcerative colitis etc.
• Females of child-bearing potential who are pregnant or lactating or
who are not using adequate contraception.
E.5 End points
E.5.1 Primary end point(s)
The primary endpoint of this study is overall survival (OS) compared between patients randomized to DCVax-L and control patients from comparable, contemporaneous trials who received standard of care therapy only, in patients with newly diagnosed glioblastoma.
E.5.1.1 Timepoint(s) of evaluation of this end point
October 2020
E.5.2 Secondary end point(s)
The first secondary endpoint is overall survival (OS) compared between patients randomized to placebo who received DCVax-L treatment following disease recurrence, and control patients from comparable, contemporaneous clinical trials, in patients with recurrent GBM.
The second secondary endpoint, confirmed progression-free survival (cPFS), is confirmed disease progression (cPD) compared between subjects randomized to DCVax®-L and those randomized to Placebo within Study 020221.
The third secondary endpoint, PFS, is progression-free survival compared between subjects randomized to DCVax®-L and those randomized to Placebo within Study 020221.
The fourth secondary objective, OS, is overall survival compared between subjects randomized to DCVax®-L and those randomized to Placebo within Study 020221.
The fifth secondary objective is tumor response compared between subjects randomized to DCVax®-L and those randomized to Placebo within Study 020221.
E.5.2.1 Timepoint(s) of evaluation of this end point
October 2020
E.6 and E.7 Scope of the trial
E.6 Scope of the trial
E.6.1 Diagnosis No
E.6.2 Prophylaxis No
E.6.3 Therapy Yes
E.6.4 Safety Yes
E.6.5 Efficacy Yes
E.6.6 Pharmacokinetic No
E.6.7 Pharmacodynamic No
E.6.8 Bioequivalence No
E.6.9 Dose response No
E.6.10 Pharmacogenetic No
E.6.11 Pharmacogenomic No
E.6.12 Pharmacoeconomic No
E.6.13 Others No
E.7 Trial type and phase
E.7.1 Human pharmacology (Phase I) No
E.7.1.1 First administration to humans No
E.7.1.2 Bioequivalence study No
E.7.1.3 Other No
E.7.1.3.1 Other trial type description
E.7.2 Therapeutic exploratory (Phase II) No
E.7.3 Therapeutic confirmatory (Phase III) Yes
E.7.4 Therapeutic use (Phase IV) No
E.8 Design of the trial
E.8.1 Controlled Yes
E.8.1.1 Randomised Yes
E.8.1.2 Open No
E.8.1.3 Single blind No
E.8.1.4 Double blind Yes
E.8.1.5 Parallel group Yes
E.8.1.6 Cross over Yes
E.8.1.7 Other No
E.8.2 Comparator of controlled trial
E.8.2.1 Other medicinal product(s) No
E.8.2.2 Placebo Yes
E.8.2.3 Other No
E.8.2.4 Number of treatment arms in the trial 2
E.8.3 The trial involves single site in the Member State concerned No
E.8.4 The trial involves multiple sites in the Member State concerned Yes
E.8.4.1 Number of sites anticipated in Member State concerned 3
E.8.5 The trial involves multiple Member States Yes
E.8.5.1 Number of sites anticipated in the EEA 25
E.8.6 Trial involving sites outside the EEA
E.8.6.1 Trial being conducted both within and outside the EEA Yes
E.8.6.2 Trial being conducted completely outside of the EEA No
E.8.6.3 If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
Germany
United Kingdom
United States
E.8.7 Trial has a data monitoring committee Yes
E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
LVLS
E.8.9 Initial estimate of the duration of the trial
E.8.9.1 In the Member State concerned years 3
E.8.9.1 In the Member State concerned months 0
E.8.9.1 In the Member State concerned days 0
E.8.9.2 In all countries concerned by the trial years 6
E.8.9.2 In all countries concerned by the trial months 0
E.8.9.2 In all countries concerned by the trial days 0
F. Population of Trial Subjects
F.1 Age Range
F.1.1 Trial has subjects under 18 No
F.1.1.1 In Utero No
F.1.1.2 Preterm newborn infants (up to gestational age < 37 weeks) No
F.1.1.3 Newborns (0-27 days) No
F.1.1.4 Infants and toddlers (28 days-23 months) No
F.1.1.5 Children (2-11years) No
F.1.1.6 Adolescents (12-17 years) No
F.1.2 Adults (18-64 years) Yes
F.1.2.1 Number of subjects for this age range: 288
F.1.3 Elderly (>=65 years) Yes
F.1.3.1 Number of subjects for this age range: 60
F.2 Gender
F.2.1 Female Yes
F.2.2 Male Yes
F.3 Group of trial subjects
F.3.1 Healthy volunteers No
F.3.2 Patients Yes
F.3.3 Specific vulnerable populations No
F.3.3.1 Women of childbearing potential not using contraception No
F.3.3.2 Women of child-bearing potential using contraception Information not present in EudraCT
F.3.3.3 Pregnant women No
F.3.3.4 Nursing women No
F.3.3.5 Emergency situation Information not present in EudraCT
F.3.3.6 Subjects incapable of giving consent personally No
F.3.3.7 Others No
F.4 Planned number of subjects to be included
F.4.1 In the member state 24
F.4.2 For a multinational trial
F.4.2.1 In the EEA 132
F.4.2.2 In the whole clinical trial 348
F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
Patients will be treated by their physicians according to the current standard of care.
G. Investigator Networks to be involved in the Trial
N. Review by the Competent Authority or Ethics Committee in the country concerned
N. Competent Authority Decision Authorised
N. Date of Competent Authority Decision 2012-08-01
N. Ethics Committee Opinion of the trial application Favourable
N. Ethics Committee Opinion: Reason(s) for unfavourable opinion
N. Date of Ethics Committee Opinion 2011-10-05
P. End of Trial
P. End of Trial Status Restarted
As of 1.2.2020, the UK is no longer an EU Member State. However, EU law still applies to the UK during the transition period
EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
European Medicines Agency © 1995-2020 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands Legal notice
EMAHMA
wow maybe
LOL just a little humor for the weekend If it helps 1/2 yard line we are winning this 100PCT
Very Nice... Or everyone on this board has a 50-50 shot what 50 would you want to be on.
Honestly Marzan it wont matter. The reward is going to blow away any risk now. We all have plenty of dry powder waiting, They know it and we know it If they try and push it down minus .10-.15 it will be nothing compared to the results $5-$10 to all the longs enjoy your weekend THE BEST IS YET TO COME....
It was my understanding they are comfortable with the warrants on Nov 1 not worried
maybe close but still have another gap around .87 they may try and push it down one last time using election day Tuesday and Nov 1 excuse . Most of those warrants I believe are in safe hands will will not be exercised I am ready to pounce if they do
YES right during that dip to 1.09-1.11 for like 3-5 min I tried to buy 10 different times REJECTED ameritrade. Then it let me in .
all i know is i never had a problem with any buy order before. Today at $1.11 i tried to buy 500 shares to 50000 shares and it would not take it? You tell me
. ive been around for 8 years watching /buying and yes we bought alot at .17 .24 .36 and 5$ & 7$ and even some at 9$ back in the day.
odd for 5 min during that dip i tried buying every order rejected 10 straight orders small and large now no problem
Anyone getting rejected orders to buy right now ?
maybe Biogen biib
Angel investors for a reason... Have faith....
The large warrant holders are still holding. Shorts are very good at what they do. Hang on buy the big dips if you can. They will do the same they know whats coming. GL longs
Thats Great
Feel Better Sojo... We will hold down the ship while you recover.
Where is SIr Pumper we need a little hello from him.
Search News
Traders Have Rotated Into Big Multinational Companies On OTC Markets
Today 8:04 AM ET (Benzinga)Print
One of the ways we gauge market sentiment is by looking at rotation—which areas of the market, traders and investors are most bullish or bearish on, and watching how those trends change over time.
Venture Companies With The Highest Volume Increases
On the OTCQB Venture Market, Relief Therapeutics Holding (OTCQB: RLFTF), NORTHWEST BIOTHERAPEUTICS, INC. (OTCQB: NWBO), GIGA METALS Corp (OTCQB: HNCKF), and Basanite Inc. (OTCQB: BASA) all had dollar volume spikes of over 700% in September compared to August.
For 2020, CytoDyn Inc. (OTCQB: CYDY) and Fannie Mae (OTCQB: FNMA) remain the most actively traded securities on the OTCQB Market, with over $6 billion of annual dollar volume between them.
Below are the top 10 most actively traded securities on the OTCQX and OTCQB Markets In September.
$136,863,313
Northwest Biotherapeutics, Inc.
NWBO
USA
$131,245,748
Fannie Mae
FNMA
USA
$88,982,010
Galaxy Next Generation, Inc.
GAXY
USA
$75,238,072
Giga Metals Corp
HNCKF
Canada
$64,126,316
Freddie Mac
FMCC
USA
$48,682,394
MIND MEDICINE MINDMED INC.
MMEDF
Canada
$32,071,632
DSG Global Inc
DSGT
Canada
$29,909,294
Humanigen, Inc.
HGEND
USA
$28,028,966
Exactly... Maybe Cofer Black can chart that one.
Good Night Sojourner55 Thanks for all that you do.... hope to hear from you soon you have been great for all of longs...
I don’t think that will get rid of him. Good idea but I’m afraid we are stuck with him.
Marzan I saw that.. What do you think that was?
Serious side effects
KEYTRUDA is a medicine that may treat certain cancers by working with your immune system. KEYTRUDA can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life-threatening and can lead to death. These problems may happen anytime during treatment or even after your treatment has ended.
Related topics
Sign up for support
Taking KEYTRUDA
How does KEYTRUDA work?
Immunotherapy treatment tips
Tips for managing your treatment
Call or see your doctor right away if you develop any symptoms of the following problems or these symptoms get worse:
Lung problems (pneumonitis)
Shortness of breath
Chest pain
New or worse cough
Intestinal problems (colitis) that can lead to tears or holes in your intestine
Diarrhea or more bowel movements than usual
Stools that are black, tarry, sticky, or have blood or mucus
Severe stomach-area (abdomen) pain or tenderness
Liver problems, including hepatitis
Yellowing of your skin or the whites of your eyes
Nausea or vomiting
Pain on the right side of your stomach area (abdomen)
Dark urine
Bleeding or bruising more easily than normal
Kidney problems, including nephritis and kidney failure
Change in the amount or color of your urine
Skin problems
Rash
Itching
Blisters, peeling or skin sores
Painful sores or ulcers in your mouth or in your nose, throat, or genital area
Hormone gland problems (especially the thyroid, pituitary, adrenal glands, and pancreas)
Rapid heart beat
Weight loss or weight gain
Increased sweating
Feeling more hungry or thirsty
Urinating more often than usual
Hair loss
Feeling cold
Constipation
Your voice gets deeper
Muscle aches
Feeling very weak
Dizziness or fainting
Headaches that will not go away or unusual headache
Problems in other organs
Changes in eyesight
Severe or persistent muscle or joint pains
Severe muscle weakness
Low red blood cells (anemia)
Swollen lymph nodes, rash or tender lumps on skin, cough, shortness of breath, vision changes, or eye pain (sarcoidosis)
Confusion, fever, muscle weakness, balance problems, nausea, vomiting, stiff neck, memory problems, or seizures (encephalitis)
Pain, numbness, tingling, or weakness in your arms or legs, or bladder or bowel problems, including the need to urinate more often, leaking of urine, trouble urinating, or constipation (myelitis)
Shortness of breath, irregular heartbeat, feeling tired, or chest pain (myocarditis)
Infusion (IV) reactions that can sometimes be severe and life-threatening
Chills or shaking
Shortness of breath or wheezing
Itching or rash
Flushing
Dizziness
Fever
Feeling like passing out
Rejection of a transplanted organ. People who have had an organ transplant may have an increased risk of organ transplant rejection. Your doctor should tell you what signs and symptoms you should report and monitor you, depending on the type of organ transplant that you have had.
Complications, including graft-versus-host-disease (GVHD), in people who have received a bone marrow (stem cell) transplant that uses donor stem cells (allogeneic). These complications can be severe and can lead to death. These complications may happen if you underwent transplantation either before or after being treated with KEYTRUDA. Your doctor will monitor you for the following signs and symptoms: skin rash, liver inflammation, stomach-area (abdominal) pain, and diarrhea.
Getting medical treatment right away may help keep these problems from becoming more serious. Your doctor will check you for these problems during treatment with KEYTRUDA. Your doctor may treat you with corticosteroid or hormone replacement medicines. Your doctor may also need to delay or completely stop treatment with KEYTRUDA, if you have severe side effects.
I agree Flipper we may never see $1.60 ever again. or .16 again Im glad I was in back then
Yep Look at buys last hour. Someone was very smart with when and how much. Dips were hit several times with nice buys.
Sojourner55 I agree with your read on this. Take some profits add dry powder and buy on emotional Dips
Free shares. In the end nothing has changed with the Trial Results and we all know it.. They will be game changing as well as life changing.
Yep Added again
You a good man Sir Pump Thank you for all that you do. Gary our prayers are with you and your family ,
Its business period. Linda has them right where she wants She has the best answer for cancer and now she has the best chance to get it done. She knows it. They know it and soon everyone will see it.
LONG NWBO!!!!
We are all battle tested and educated We know the science and have been here for many many years. Not going to shake weak hands with us.
That is a Beautiful Chart